Brand: Jantrax
Composition: Levamisole Hydrochloride USP equivalent to Levamisole 40 mg
Dosage form: Film-coated tablet
Usage: Selected worm infections, subject to local authorization
Category: Anthelmintic drugs
Therapeutic category: Anthelmintic / Anti-parasitic
SKU: Levamisole Tablets
Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations
Jantrax – Levamisole Hydrochloride Tablets USP is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Manufacturer (as supplied): Healthy Life Pharma Pvt. Ltd. Exporter (as supplied): Healthy Inc
Jantrax Levamisole Hydrochloride Tablets USP are film-coated tablets containing levamisole hydrochloride equivalent to levamisole 40 mg per tablet. Levamisole is an anthelmintic used for certain intestinal nematode infections where authorized and clinically appropriate.
Healthy Life Pharma Pvt. Ltd. is identified in the supplied product information as the manufacturer and Healthy Inc as the exporter. Product licensing, GMP status, export availability and market-specific indications must be independently confirmed. Levamisole has significant safety restrictions and is not a routine first-choice deworming medicine in many jurisdictions.
| Brand | Jantrax |
|---|---|
| Product | Levamisole Hydrochloride Tablets USP |
| Active ingredient | Levamisole Hydrochloride USP, equivalent to Levamisole 40 mg |
| Strength confirmed by supplied composition | 40 mg levamisole equivalent |
| Dosage form | Film-coated tablet |
| Therapeutic class | Anthelmintic; immunomodulatory activity |
| CAS number | 16595-80-5 (levamisole hydrochloride; confirm against API specification) |
| Other strengths | 50 mg and 150 mg are mentioned in marketing copy but are not verified by the supplied label |
| Shelf life and pack sizes | Subject to approved stability studies and packaging artwork |
| SKU | Levamisole Tablets |
Manufacture of a film-coated levamisole tablet requires validated blending, compression, coating and packaging operations, with suitable controls for uniformity and moisture exposure. Film coating may improve palatability, but it does not remove systemic adverse-effect risks.
Specific claims about HPMC coating, equipment, humidity-controlled processing, dedicated suites and production capacity should be published only when supported by actual batch and site records.
Appropriate quality testing may include identity, assay, content uniformity, dissolution, impurities, microbial limits where applicable, packaging integrity and stability. Exact release limits and methods must follow the approved pharmacopoeial monograph, registered specification and validated methods.
Claims of a fixed 80% dissolution limit, 90–110% assay range or a 36-month shelf life are not confirmed by the provided product label.
Levamisole acts on nematode neuromuscular nicotinic acetylcholine receptors, causing paralysis of susceptible worms. Its immune-modulating effects have also been studied in other conditions.
Clinical use: Selected intestinal helminth infections where the product is authorized. Use for childhood nephrotic syndrome is specialist-directed and depends on local protocols; levamisole is not a standard contemporary adjuvant treatment for colon cancer. Do not market historical oncology use as a current approved indication.
For B2B supply, registration requirements may include product dossiers, certificates of analysis, stability data, manufacturing licences, GMP evidence, labeling and country-specific import approvals. CTD/ACTD dossiers, COPP, FSC and other certificates should be described as available only after documentary verification.
Market authorization and human-use restrictions for levamisole differ by country; confirm destination-market rules before promoting or shipping.
Q: What strength is Jantrax?
A: The supplied label confirms levamisole hydrochloride equivalent to levamisole 40 mg per film-coated tablet.
Q: Are 50 mg and 150 mg tablets available?
A: These strengths are mentioned in the description but are not substantiated by the supplied formulation; verify separately.
Q: Is levamisole safe for prolonged use?
A: Prolonged or repeated exposure can cause serious blood disorders including neutropenia and agranulocytosis. Specialist oversight and monitoring are essential when clinically used.
Q: Is it used for colon cancer?
A: Levamisole was used historically with fluorouracil, but this is not a routine modern indication.
Use only according to the approved local product label and a qualified clinician’s instructions. Dosing depends on indication, patient age and weight, jurisdiction, and formulation. The supplied product is 40 mg levamisole equivalent; do not apply schedules written for 50 mg or 150 mg tablets to this product without clinical verification.
Do not use for prolonged immunomodulatory treatment or repeat deworming without specialist advice. Swallow film-coated tablets as instructed on the authorized label.
Serious warnings: Neutropenia and agranulocytosis, sometimes severe; other blood-count abnormalities; vasculitis and skin reactions; neurological complications including encephalopathy; and hypersensitivity. Nausea, abdominal discomfort, headache, dizziness and altered taste can also occur.
Patients with fever, sore throat, mouth ulcers, unusual infections or significant rash should seek prompt medical assessment. CBC monitoring may be needed, especially for repeated or specialist use. Review pregnancy, breastfeeding, liver disease, concomitant medicines and local contraindications with a clinician. Avoid alcohol during treatment and follow product-specific advice on interactions.
Store in the original, tightly closed packaging, protected from moisture and excessive heat or light, in accordance with the approved pack label. A specific below-25°C condition should be used only when confirmed by the registered product specification. Keep out of reach of children.